Tandem Diabetes posted third-quarter results that included revenue growth of 14% in constant currency, and gross margin that improved by 270 basis points year over year. International sales growth of 27% was particularly strong.
Tandem’s t:slim X2 features a low-profile, color touchscreen that is very user-friendly for patients new to insulin pumps.
Bears
MiniMed arguably enjoys more accurate and advanced algorithms thanks to its far larger patient user base and proprietary data—a major reason why it remains a step ahead of Tandem in closing the loop.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.